Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

263.67
-15.3456-5.50%
Volume:239.82K
Turnover:64.08M
Market Cap:494.25M
PE:- -
High:274.71
Open:265.00
Low:260.01
Close:279.02
52wk High:341.93
52wk Low:74.95
Shares:1.87M
Float Shares:1.87M
Volume Ratio:0.86
T/O Rate:12.79%
Dividend:1.00
Dividend Rate:0.38%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Regis Healthcare Ltd. (REG) Receives a Buy from Macquarie

TIPRANKS
·
Sep 04

Sino Biopharma Gets US FDA Investigational New Drug Approval for Tumor Drug

MT Newswires Live
·
Sep 04

Health Care Flat on Rotation to Rate-Sensitive Sectors - Health Care Roundup

Dow Jones
·
Sep 04

Health Care Roundup: Market Talk

Dow Jones
·
Sep 04

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

GlobeNewswire
·
Sep 04

PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference

GlobeNewswire
·
Sep 04

Alector to Participate in Upcoming Healthcare Conferences

GlobeNewswire
·
Sep 04

Xenon to Present at Wells Fargo Healthcare Conference

GlobeNewswire
·
Sep 04

FDA approves Ionis drug to treat Alexander disease

TIPRANKS
·
Sep 04

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 04

Sector Update: Healthcare

MT Newswires Live
·
Sep 04

Analysts’ Top Healthcare Picks: Dogwood Therapeutics (DWTX), Quoin Pharmaceuticals (QNRX)

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

Health Care Roundup: Market Talk

Dow Jones
·
Sep 04

Analysts’ Top Healthcare Picks: Align Tech (ALGN), Eledon Pharmaceuticals (ELDN)

TIPRANKS
·
Sep 03

Spire Healthcare grants Toscafund brief extension on potential 250p-per-share bid

TIPRANKS
·
Sep 03

Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)

TIPRANKS
·
Sep 03

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Sep 03

J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential

TIPRANKS
·
Sep 03